ReviewNature reviews. Drug discovery2003
Recent advances in the discovery and delivery of vaccine adjuvants.
Review in Nature reviews. Drug discovery, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01081847 (Malaria Vaccine Phase IB Clinical Trial), which is not on this map. Cited by 125 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Malaria Vaccine Phase IB Clinical Trial: Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants
Who cites it
125 citing papers in PubMed.
- Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.The American journal of tropical medicine and hygiene · 2011Trial
- Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G.Clinical and vaccine immunology : CVI · 2008Trial
- Rational design of next-generation vaccine adjuvants: From molecular mechanisms to hybrid delivery platforms.Human vaccines & immunotherapeutics · 2026Review
- Endogenous living adjuvants for cancer vaccination: Concepts, mechanisms, and design principles.Materials today. Bio · 2026Article
- Vaccination-enabled immune readiness for checkpoint blockade.Frontiers in immunology · 2026Review
- Proteomic Analysis of Influenza.Advances in experimental medicine and biology · 2026Review
- Adjuvant conditioning enhances neutrophil function while inducing a suppressive peritoneal macrophage phenotype.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Accessing robust vaccine coformulation stability by single adjuvant detection on a microelectrode.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Article
- Leaf Saponins ofPharmaceutics · 2025Review
- Review
- Next-Generation Vaccine Platforms: Integrating Synthetic Biology, Nanotechnology, and Systems Immunology for Improved Immunogenicity.Vaccines · 2025Review
- Synthetic Polymers for Drug, Gene, and Vaccine Delivery.Polymer science & technology (Washington, D.C.) · 2025Review
- Q Fever Vaccines: Unveiling the Historical Journey and Contemporary Innovations in Vaccine Development.Vaccines · 2025Review
- Nanotechnology-based strategies for vaccine development: accelerating innovation and delivery.Biomaterials translational · 2025Review
- Role of Adjuvants in Enhancing the Efficacy and Duration of Anesthesia Blocks: A Comprehensive Review.Cureus · 2024Review
- A comprehensive comparison of DNA and RNA vaccines.Advanced drug delivery reviews · 2024Review
- Vaccine adjuvants: current status, research and development, licensing, and future opportunities.Journal of materials chemistry. B · 2024Review
- Evaluation of different types of adjuvants in a malaria transmission-blocking vaccine.International immunopharmacology · 2024Article
- Vaccine adjuvants: mechanisms and platforms.Signal transduction and targeted therapy · 2023Review
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adjuvant design has historically had a touch of alchemy at its heart due to its reliance on the complex biology of innate immune activation. However, a new mechanistic understanding of innate immunity, combined with new adjuvant and delivery platforms for exploiting this knowledge, has led to significant advances recently. Although many challenges remain, the field is moving rapidly and the proper tools and methodologies are in place for the use of traditional drug discovery engines in guiding the development of vaccine adjuvants. In this review, we outline the current trends in immune potentiator, delivery system and adjuvant design that will shape the vaccines of the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.